Companies: 10,795·Total market cap: $144.5T
Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc.

ACRSNASDAQHealthcare● Active
$4.36
+$0.00(+0.00%)
Market Cap$525794200
P/E Ratio
52W High$5.15
52W Low$1.343

Aclaris Therapeutics, Inc. (ACRS) Revenue

Annual & quarterly revenue history · segment & region breakdown

ACRS · revenue · updated Jun 9, 2026

Core revenue metrics

Aclaris Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.01B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.01B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
62.84×
mktCap ÷ TTM rev
Revenue per day
$0M
Est. TTM ÷ 365
Revenue / employee
$137K
61 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Aclaris Therapeutics, Inc. SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
ACRS revenue by year · ACRS revenue history · ACRS annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Aclaris Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Aclaris Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Aclaris Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

ACRS revenue · 4 questions

ACRS's trailing twelve-month (TTM) revenue is $0.01B. That is an increase of 0.00% year-over-year from — in FY.

ACRS revenueACRS annual revenuewhat is ACRS revenueACRS TTM revenue

Source: FMP · Aclaris Therapeutics, Inc. SEC filings · GAAP · Aclaris Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026